Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 5010, Tv
2. Acetate, Glatiramer
3. Copaxone
4. Glatiramer
5. Tv 5010
6. Tv-5010
7. Tv5010
1. 147245-92-9
2. Acetic Acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic Acid;(2s)-2-aminopentanedioic Acid;(2s)-2-aminopropanoic Acid;(2s)-2,6-diaminohexanoic Acid
3. Glatirameracetat
4. Dtxsid30163637
5. Am84438
6. Ac-28732
7. L-alanine Compound With L-glutamic Acid And L-lysine And L-tyrosine And Acetic Acid (1:1:1:1:1)
8. Q418274
1. Glat Copolymer
2. Tgal Copolymer
3. Synthetic Peptide Copolymer I
4. Glatiramer
| Molecular Weight | 623.7 g/mol |
|---|---|
| Molecular Formula | C25H45N5O13 |
| Hydrogen Bond Donor Count | 12 |
| Hydrogen Bond Acceptor Count | 18 |
| Rotatable Bond Count | 13 |
| Exact Mass | 623.30138651 g/mol |
| Monoisotopic Mass | 623.30138651 g/mol |
| Topological Polar Surface Area | 374 Ų |
| Heavy Atom Count | 43 |
| Formal Charge | 0 |
| Complexity | 519 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 5 |
| 1 of 2 | |
|---|---|
| Drug Name | Copaxone |
| PubMed Health | Glatiramer (Injection) |
| Drug Classes | Central Nervous System Agent, Immune Suppressant, Musculoskeletal Agent |
| Drug Label | Glatiramer acetate, the active ingredient of COPAXONE, consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.... |
| Active Ingredient | Glatiramer acetate |
| Dosage Form | Injectable |
| Route | Subcutaneous |
| Strength | 20mg/ml; 40mg/ml |
| Market Status | Prescription |
| Company | Teva Pharms Usa |
| 2 of 2 | |
|---|---|
| Drug Name | Copaxone |
| PubMed Health | Glatiramer (Injection) |
| Drug Classes | Central Nervous System Agent, Immune Suppressant, Musculoskeletal Agent |
| Drug Label | Glatiramer acetate, the active ingredient of COPAXONE, consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.... |
| Active Ingredient | Glatiramer acetate |
| Dosage Form | Injectable |
| Route | Subcutaneous |
| Strength | 20mg/ml; 40mg/ml |
| Market Status | Prescription |
| Company | Teva Pharms Usa |
Antirheumatic Agents
Drugs that are used to treat RHEUMATOID ARTHRITIS. (See all compounds classified as Antirheumatic Agents.)
Immunosuppressive Agents
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)
Adjuvants, Immunologic
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)
L03AX13
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
L - Antineoplastic and immunomodulating agents
L03 - Immunostimulants
L03A - Immunostimulants
L03AX - Other immunostimulants
L03AX13 - Glatiramer acetate
Details:
Alemtuzumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Multiple Sclerosis.
Lead Product(s):
Alemtuzumab,Glatiramer Acetate,Interferon Beta,Methylprednisolone,Ranitidine,Cetirizine,Dexchloropheniramine Maleate,Paracetamol,Acyclovir,
Therapeutic Area: Neurology
Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibody, Unconjugated Sponsor:
Undisclosed
Deal Size: Inapplicable
Upfront Cash: Inapplicable
Deal Type: Inapplicable
December 11, 2017
Lead Product(s) : Alemtuzumab, Glatiramer Acetate, Methylprednisolone, Ranitidine, Cetirizine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Alemtuzumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Multiple Sclerosis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 11, 2017
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Glatiramer Acetate, a miscellaneous product targeting polymers, shows promise in treating Multiple Sclerosis (MS).
Lead Product(s): Glatiramer Acetate,Inapplicable
Therapeutic Area: Neurology Brand Name: Copaxone-Generic
Study Phase: Approved FDFProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 05, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Glatiramer Acetate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ScinoPharm Gets US FDA Nod for Glatiramer Acetate Injection in Multiple Sclerosis
Details : Glatiramer Acetate, a miscellaneous product targeting polymers, shows promise in treating Multiple Sclerosis (MS).
Product Name : Copaxone-Generic
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
January 05, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Copaxone-Generic (glatiramer acetate) is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease.
Lead Product(s): Glatiramer Acetate,Inapplicable
Therapeutic Area: Neurology Brand Name: Copaxone-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 09, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Glatiramer Acetate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus gets USFDA nod for generic drug to treat multiple sclerosis
Details : Copaxone-Generic (glatiramer acetate) is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease.
Product Name : Copaxone-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 09, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Copaxone Depot, a long-acting glatiramer acetate designed to be administered as an intramuscular injection, is being investigated as a once-monthly injection for the treatment of relapsing forms of multiple sclerosis (RMS).
Lead Product(s): Glatiramer Acetate,Inapplicable
Therapeutic Area: Neurology Brand Name: WhisperJECT
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Mapi Pharma
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 07, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Glatiramer Acetate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Mapi Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Copaxone Depot, a long-acting glatiramer acetate designed to be administered as an intramuscular injection, is being investigated as a once-monthly injection for the treatment of relapsing forms of multiple sclerosis (RMS).
Product Name : WhisperJECT
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 07, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Copaxone (glatiramer acetate) its ability to induce the peripheral Th2 cells and their subsequent crossing of the blood barrier allows for the reduction of further inflammation within the CNS.
Lead Product(s): Glatiramer Acetate,Inapplicable
Therapeutic Area: Oncology Brand Name: Copaxone
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 03, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Glatiramer Acetate,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Kinimmune Publishes Results from A Phase I “Window of Opportunity” Trial in Patients with Soli...
Details : Copaxone (glatiramer acetate) its ability to induce the peripheral Th2 cells and their subsequent crossing of the blood barrier allows for the reduction of further inflammation within the CNS.
Product Name : Copaxone
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 03, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The study evaluating a long-acting glatiramer acetate (copaxone) injection, GA Depot 40 mg once every four weeks, met the primary endpoint, significantly reducing the annualized relapse rate (ARR) by 30.1 percent compared to placebo.
Lead Product(s): Glatiramer Acetate,Inapplicable
Therapeutic Area: Neurology Brand Name: GA Depot
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Viatris
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 21, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Glatiramer Acetate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Viatris
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study evaluating a long-acting glatiramer acetate (copaxone) injection, GA Depot 40 mg once every four weeks, met the primary endpoint, significantly reducing the annualized relapse rate (ARR) by 30.1 percent compared to placebo.
Product Name : GA Depot
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 21, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
At AAN, company will be presenting 5 year data from Phase IIa study in RRMS. Also, the results seeN in the ongoing Phase II study for GA Depot in primary progressive MS (PPMS) patients, to be presented at the meeting as plan to initiate a Phase-3 for PPMS at the end of 2022.
Lead Product(s): Glatiramer Acetate,Inapplicable
Therapeutic Area: Neurology Brand Name: GA Depot
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 31, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Glatiramer Acetate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : At AAN, company will be presenting 5 year data from Phase IIa study in RRMS. Also, the results seeN in the ongoing Phase II study for GA Depot in primary progressive MS (PPMS) patients, to be presented at the meeting as plan to initiate a Phase-3 for PPM...
Product Name : GA Depot
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 31, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
GA Depot is a long-acting injection version of the approved Copaxone® (Glatiramer Acetate) designed to be administered as an intramuscular injection once every four weeks, is being evaluated for treatment of relapsing forms of multiple sclerosis.
Lead Product(s): Glatiramer Acetate,Inapplicable
Therapeutic Area: Neurology Brand Name: GA Depot
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 30, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Glatiramer Acetate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GA Depot is a long-acting injection version of the approved Copaxone® (Glatiramer Acetate) designed to be administered as an intramuscular injection once every four weeks, is being evaluated for treatment of relapsing forms of multiple sclerosis.
Product Name : GA Depot
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 30, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The label update of COPAXONE® (Glatiramer Acetate) follows the review of clinical and non-clinical evidence, including latest data from the COBRA study that investigated safety outcomes in infants breastfed by mothers with MS undergoing GA treatment during the first 18 months.
Lead Product(s): Glatiramer Acetate,Inapplicable
Therapeutic Area: Neurology Brand Name: Copaxone
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 10, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Glatiramer Acetate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
COPAXONE® Label Now Indicates Its Use in Breastfeeding Mothers with Relapsing Multiple Sclerosis
Details : The label update of COPAXONE® (Glatiramer Acetate) follows the review of clinical and non-clinical evidence, including latest data from the COBRA study that investigated safety outcomes in infants breastfed by mothers with MS undergoing GA treatment dur...
Product Name : Copaxone
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 10, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Patients were eligible for the study if they were diagnosed with relapsing MS (RMS), gave a live birth, were breastfeeding under GA treatment (COPAXONE® 20 or 40 mg/mL) or breastfeeding under no DMT treatment.
Lead Product(s): Glatiramer Acetate,Inapplicable
Therapeutic Area: Neurology Brand Name: Copaxone
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 13, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Glatiramer Acetate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
New Safety Data on Treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Liv...
Details : Patients were eligible for the study if they were diagnosed with relapsing MS (RMS), gave a live birth, were breastfeeding under GA treatment (COPAXONE® 20 or 40 mg/mL) or breastfeeding under no DMT treatment.
Product Name : Copaxone
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 13, 2021

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
48
PharmaCompass offers a list of Glatiramer Acetate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Glatiramer Acetate manufacturer or Glatiramer Acetate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Glatiramer Acetate manufacturer or Glatiramer Acetate supplier.
A L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt), including repackagers and relabelers. The FDA regulates L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) supplier is an individual or a company that provides L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) active pharmaceutical ingredient (API) or L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) finished formulations upon request. The L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) suppliers may include L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) API manufacturers, exporters, distributors and traders.
click here to find a list of L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) DMF (Drug Master File) is a document detailing the whole manufacturing process of L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) active pharmaceutical ingredient (API) in detail. Different forms of L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) DMFs exist exist since differing nations have different regulations, such as L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) DMF submitted to regulatory agencies in the US is known as a USDMF. L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) USDMF includes data on L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt)'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) suppliers with USDMF on PharmaCompass.
A L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) written confirmation (L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) WC) is an official document issued by a regulatory agency to a L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) manufacturer, verifying that the manufacturing facility of a L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) APIs or L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) finished pharmaceutical products to another nation, regulatory agencies frequently require a L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) WC (written confirmation) as part of the regulatory process.
click here to find a list of L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) suppliers with NDC on PharmaCompass.
L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) GMP manufacturer or L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) GMP API supplier for your needs.
A L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) CoA (Certificate of Analysis) is a formal document that attests to L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt)'s compliance with L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) specifications and serves as a tool for batch-level quality control.
L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) CoA mostly includes findings from lab analyses of a specific batch. For each L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) may be tested according to a variety of international standards, such as European Pharmacopoeia (L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) EP), L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) JP (Japanese Pharmacopeia) and the US Pharmacopoeia (L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) USP).